45.79
Precedente Chiudi:
$45.28
Aprire:
$45.53
Volume 24 ore:
220.04K
Relative Volume:
0.45
Capitalizzazione di mercato:
$1.45B
Reddito:
$566.77M
Utile/perdita netta:
$48.16M
Rapporto P/E:
38.48
EPS:
1.19
Flusso di cassa netto:
$274.29M
1 W Prestazione:
-3.82%
1M Prestazione:
-3.15%
6M Prestazione:
+20.95%
1 anno Prestazione:
+47.81%
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Nome
Collegium Pharmaceutical Inc
Settore
Telefono
781-713-3699
Indirizzo
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
COLL
Collegium Pharmaceutical Inc
|
45.79 | 1.43B | 566.77M | 48.16M | 274.29M | 1.19 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.46 | 58.03B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.65 | 55.37B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.20 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.98 | 39.50B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.66 | 20.50B | 3.13B | 1.27B | 1.12B | 26.39 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-01-10 | Aggiornamento | Needham | Hold → Buy |
| 2024-07-30 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-06-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-05-10 | Downgrade | Needham | Buy → Hold |
| 2024-05-10 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-01-04 | Downgrade | Jefferies | Buy → Hold |
| 2023-08-25 | Reiterato | Needham | Buy |
| 2023-05-02 | Ripresa | Jefferies | Buy |
| 2022-08-08 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-02-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-08-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-01-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-14 | Iniziato | BWS Financial | Sell |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-02-19 | Ripresa | Jefferies | Buy |
| 2019-10-30 | Reiterato | Needham | Buy |
| 2019-05-03 | Ripresa | H.C. Wainwright | Buy |
| 2019-04-12 | Ripresa | Janney | Buy |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2019-01-16 | Reiterato | Needham | Buy |
| 2018-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2018-02-07 | Reiterato | Needham | Buy |
| 2017-12-05 | Reiterato | Needham | Buy |
| 2017-09-11 | Iniziato | H.C. Wainwright | Buy |
| 2017-05-11 | Reiterato | Needham | Buy |
| 2016-09-13 | Iniziato | Gabelli & Co | Buy |
| 2015-06-01 | Iniziato | Jefferies | Buy |
| 2015-06-01 | Iniziato | Needham | Buy |
| 2015-06-01 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Collegium Pharmaceutical Inc Borsa (COLL) Ultime notizie
Is Collegium Pharmaceutical Inc. a good stock for dollar cost averaging2025 Risk Factors & Real-Time Volume Surge Alerts - mfd.ru
(COLL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026 - Yahoo Finance
Earnings Report: Whats Collegium Pharmaceutical Incs historical returnTake Profit & Reliable Entry Point Trade Alerts - baoquankhu1.vn
The Truth About Collegium Pharmaceutical (COLL): Quiet Stock, Loud Moves – Are You Sleeping On Thi - AD HOC NEWS
Truist Adjusts Price Target on Collegium Pharmaceutical to $58 From $55, Maintains Buy Rating - marketscreener.com
Truist Securities raises Collegium Pharmaceutical stock price target to $58 By Investing.com - Investing.com South Africa
Truist Securities raises Collegium Pharmaceutical stock price target to $58 - Investing.com
Versor Investments LP Purchases New Position in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Principal Financial Group Inc. Cuts Holdings in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) Presents a Classic Value Case with High Earnings and Low Valuation - ChartMill
What Collegium Pharmaceutical (COLL)'s Revenue Surge and Low Valuation Means For Shareholders - simplywall.st
Ballast Asset Management LP Purchases 27,109 Shares of Collegium Pharmaceutical, Inc. $COLL - MarketBeat
(COLL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Collegium Pharmaceutical: Quiet Chart, Loud Questions Around This Specialty Pain Stock - AD HOC NEWS
Market Moves: Is Collegium Pharmaceutical Inc trading at a discount2025 Market Sentiment & Growth Oriented Trade Recommendations - baoquankhu1.vn
Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Strong Revenue Growth and Attractive Valuation with 17.24% Upside Potential - DirectorsTalk Interviews
Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Emerald Mutual Fund Advisers Trust Sells 154,973 Shares of Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Collegium Pharmaceutical, Inc. $COLL Shares Sold by Emerald Advisers LLC - MarketBeat
Collegium Pharmaceutical: Buying The Projected Growth For 2026 - Seeking Alpha
(COLL) Risk Channels and Responsive Allocation - Stock Traders Daily
Campbell & CO Investment Adviser LLC Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL - Defense World
SG Americas Securities LLC Raises Position in Collegium Pharmaceutical, Inc. $COLL - Defense World
A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Pullback - Sahm
A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Swings - Yahoo Finance
Is It Too Late To Consider Collegium Pharmaceutical (COLL) After A 40% One Year Gain? - simplywall.st
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference - GlobeNewswire
Does Collegium’s 2026 Revenue Guidance After Insider Sales Change The Bull Case For COLL? - simplywall.st
Eastern Bank Buys 45,508 Shares of Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025 - AOL.com
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? - Yahoo Finance
Q4 Earnings Estimate for COLL Issued By HC Wainwright - Defense World
Best value stocks to buy for Dec. 18 - MSN
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Needham & Company LLC Forecasts Strong Price Appreciation for Collegium Pharmaceutical (NASDAQ:COLL) Stock - Defense World
Will Authorized Generic Nucynta Launch and New Credit Facility Change Collegium Pharmaceutical's (COLL) Narrative? - Yahoo Finance
(COLL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Can Collegium Pharmaceutical Inc. stock outperform in 2025 bull marketRisk Management & Accurate Trade Setup Notifications - Улправда
Will Collegium Pharmaceutical Inc. stock benefit from commodity pricesMarket Trend Report & AI Powered Buy/Sell Recommendations - ulpravda.ru
Is It Time To Reassess Collegium Pharmaceutical (COLL) After Its Strong Five Year Share Price Run? - Yahoo Finance
How Collegium Pharmaceutical Inc. stock performs in weak economyMarket Trend Review & Free Accurate Trade Setup Notifications - ulpravda.ru
Is Collegium Pharmaceutical Inc. stock positioned for digital transformationMarket Weekly Review & Long Hold Capital Preservation Plans - Улправда
A Look At Collegium Pharmaceutical (COLL) Valuation After 2026 Guidance And Nucynta Authorized Generic Agreements - simplywall.st
Collegium Pharmaceutical (NASDAQ:COLL) Trading Down 6.8% on Analyst Downgrade - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Price Target Cut to $56.00 by Analysts at Barclays - MarketBeat
How Good Is Collegium Pharmaceutical, Inc. (NASDAQ:COLL), When It Comes To ROE? - 富途牛牛
Collegium Pharmaceutical (NASDAQ:COLL) Price Target Raised to $56.00 - MarketBeat
Collegium Pharmaceutical Inc Azioni (COLL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Collegium Pharmaceutical Inc Azioni (COLL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dreyer Scott | EVP & Chief Commercial Officer |
Dec 08 '25 |
Option Exercise |
15.90 |
17,600 |
279,840 |
121,213 |
| Dreyer Scott | EVP & Chief Commercial Officer |
Dec 08 '25 |
Sale |
48.17 |
17,600 |
847,855 |
103,613 |
| Balice-Gordon Rita J. | Director |
Dec 05 '25 |
Sale |
47.03 |
3,650 |
171,673 |
52,629 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):